library.onepin.app/ll-37 Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider
Immune Human cathelicidin antimicrobial peptideNot FDA-approved · research compound

LL-37

Cathelicidin · LL37 · hCAP-18

25 mcg – 100-200 mcg SubQ Daily
Innate immune defense peptideMembrane-disrupting antimicrobial37-amino acid alpha-helical peptide

LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid peptide cleaved from the precursor protein hCAP18 by proteinase 3. It is a key component of the innate immune system, produced by neutrophils, macrophages, epithelial cells, and mast cells in response to infection. LL-37 directly kills bacteria, fungi, and enveloped viruses through membrane disruption, while also modulating immune cell recruitment, wound healing, and inflammatory signaling. It represents a naturally occurring antibiotic peptide that pathogens have difficulty developing resistance to due to its membrane-targeting mechanism.

Quick Start
Route
SubQ injection
Start low
25 mcg SubQ
Frequency
Daily or as needed
Timing
No fasting required

Can be taken any time. Short courses (2-4 weeks) for infections. Pin alone or with limited safe compounds only.

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Tolerance Test Dose
25 mcg · SubQ · Daily
anecdotal
First-exposure test dose. LL-37 is a mast cell degranulator; assess for flushing, itching, wheal or hypotension before escalating.
25 mcg
Daily
Expert
Antimicrobial / Biofilm Disruption
100-200 mcg · SubQ · Daily
in vitro · Overhage et al. 2008 (Infect Immun, 76:4176-4182)
Used aggressively in the community for Lyme disease or chronic viral/bacterial infections. Highly painful injection. One human study injected LL-37 directly into skin tumours in 4 people (NCT02225366). Nothing has tested it as a systemic antimicrobial in humans, so the antibacterial and biofilm evidence remains laboratory only. The study cited here is laboratory cell research. A concentration in a dish is not a dose, so this amount is community practice rather than a trial result.
100-200 mcg
Daily
Reconstitution CalculatorU-100
050100u
Draw to
units
01

How it works

LL-37 adopts an amphipathic alpha-helical structure that inserts into microbial membranes, creating pores that disrupt membrane integrity and kill pathogens. This mechanism is effective against gram-positive and gram-negative bacteria, fungi, and enveloped viruses. Beyond direct killing, LL-37 recruits immune cells to infection sites (chemotaxis), modulates inflammatory cytokine production, neutralizes bacterial endotoxin (LPS), promotes angiogenesis and wound healing, and disrupts bacterial biofilms that protect chronic infections.

02

What to expect

Early
Days 1–7

Days 1-7: Immune augmentation begins. Most relevant during active infection.

Mid
Weeks 2–4

Weeks 2-4: Chronic infection support. Biofilm disruption effects accumulate.

Later
Weeks 4–12

Short courses typical. Extended use not standard.

03

Evidence

HumanModerate
AnimalPresent
In-vitroStrong

Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.

Evidence boundary from the checked abstract: LL-37 also stimulates the migration and differentiation of mesenchymal stem cells (MSCs).

LL-37 also stimulates the migration and differentiation of mesenchymal stem cells (MSCs).

Regulation of LL-37 in Bone and Periodontium Regeneration. Life (Basel, Switzerland) · 2022 · PMID 36294968

Evidence scope. This entry supports only the exact statement quoted from the live abstract; it does not independently verify OnePin's displayed dose, route, frequency, formulation, population, or broader mechanism.

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Dose/route: 25 mcg; SubQ injection; Daily or as needed. No checked live PubMed abstract verified this exact displayed dose, route, and frequency for the same molecule/formulation and relevant population.

Primary safety claim: No primary safety text present in source JSON. No checked live PubMed abstract directly verified this source-JSON safety claim at the displayed formulation, route, and regimen.

04

The honest take

Natural antibiotic

Confirmed. LL-37 directly kills pathogens through membrane disruption. Resistance development is difficult because mechanism targets fundamental membrane structure.

Biofilm disruption
Supported

Confirmed in vitro and animal models. Relevant for chronic infections with biofilm component.

05

Interactions & stacking

Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.

Documented together

BPC-157LL-37 antimicrobial + BPC tissue repair
TB-500LL-37 antimicrobial + TB systemic repair
GHK-CuNon-overlapping mechanisms
KPVLL-37 antimicrobial + KPV anti-inflammatory

Keep separate

CJC-1295 with DACDAC maleimide reactivity concern.

Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.

06

Side effects & safety

Commonly reported

  • Injection site irritation
  • Mild redness

Less common & notes

  • LL-37 is endogenously produced.
  • At high concentrations, antimicrobial peptides can theoretically be cytotoxic to host cells.
  • Stick to standard dosing ranges.
07

Pharmacokinetics

Illustrative plasma concentration · 2.1 h
Half-life
0.5h
Peak · Tmax
0.15h
Elimination
2.5h
Bioavailability
~100%

SubQ

Duration of action
6-12 hours

Antimicrobial and immune signaling effects

Clearance

Enzymatic degradation (proteases at site of action)

Storage. Standard BAC water 2-8C. Stable for 28 days. Protect from light.

08

Regulatory status

Not FDA-approved as injectable. Available as research peptide. WADA status not specifically listed.

Put it to work

Calculate, log & track

Open LL-37 straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open LL-37 in the app →

Go deeper

The guide & community

The complete LL-37 walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community

Track it in OnePin. Log vials, draws, and protocols in the app.